Friday, September 29, 2017

Mannitol

Availability:
  • Mannitol 10% (INFUSOL®M10)
  • Mannitol 20% (INFUSOL®M20)
Composition:
                                             10%                                     20%
Mannitol                                10g                                       20g
Water for Injection to          100mL                                  100mL
Osmolarity                        550mOsm/L                       1100mOsm/L

Dosing and Administration for Diuretic:


Adult
Paediatric
Dose: 50-100 gram of Mannitol  

Administration: rate adjusted to maintain urine flow of at least 30-50mL per hour.

Dose: 0.25-2g/kg

 Administration: 2-6 hours

Dosing and Administration for Cerebral Oedema or Elevated Intracranial Bleeding or Glaucoma:

Adult
Paediatric
Dose: 0.25-2g/kg

Administration: 30 to 60 minutes

Dose: 1-2g/kg

 Administration: 30 to 60 minutes
 

References:
1. INFUSOL®M10 and M20 product Information
3. Micromedex
4. Lexicomp
5. Formulari Ubat KKM, March 2016.

Rate control in Atrial Fibrilation



  • If LVEF<40% or any sign of CHF, smallest dose of beta-blocker is recommended to achieve rate control.
  • Amiodarone is an option to patient with haemodynamic instability or severely reduced LVEF.
  • If LVEF>40%, beta-blocker or diltiazem or verapamil are recommended because of its rapid onset of action and effectiveness at high sympathetic tone compared to digoxin.
  • In both condition, digoxin may be added to achieve initial resting heart rate target which is <110bpm.
Therapy
Acute Intravenous rate control
Long-term oral rate control
Comments
Beta-Blocker
    Bisoprolol
Not available
1.25–20 mg once daily or split.
Bronchospasm is rare – in cases of asthma, recommend beta-1 selective agents (avoid carvedilol).
Contra-indicated in acute cardiac failure and a history of severe bronchospasm.
    Carvedilol
Not available
3.125–50 mg BD.
    Metoprolol
2.5–10 mg intravenous bolus

(repeated as required)
100–200 mg total daily dose

(according to preparation)
    Nebivolol
Not available
2.5–10 mg once daily or split.
    Esmolol
0.5 mg/kg intravenous bolus over
1 min; then 0.05–0.25 mg/kg/min.

Calcium Channel Blockers
    Diltiazem
15–25 mg intravenous bolus

(repeated as required)
60mg TDS up to 360mg total daily dose

(120-360mg OD modified release)
Use with caution in combination with beta-blockers. Reduce dose with hepatic impairment and start with smaller dose in renal impairment. Contra-indicated in LV failure with pulmonary congestion or LVEF <40%.
    Verapamil
2.5–10 mg intravenous bolus

(repeated as required)
40-120mg TDS

(120-480mg OD modified release)
Cardiac glycosides
    Digoxin
0.5 mg intravenous bolus

(0.75–1.5 mg over 24 hours in
divided doses)
0.0625–0.25 mg daily dose
High plasma levels associated with increased risk of death. Check renal function before starting and adapt dose in patients with CKD. Contra-indicated in patients with accessory pathways, ventricular tachycardia and hypertrophic cardiomyopathy with outflow tract obstruction.
    Digitoxin
0.4–0.6 mg intravenous bolus.
0.05–0.3 mg daily dose.
Specific Indications
    Amiodarone
300mg intravenously diluted in 250mL 5% dextrose over 30-60 minutes via central venous cannula.

*If ongoing requirement, 900mg diluted in 500-1000mL for over 24 hours.
200mg daily
Suggested as adjunctive therapy in patients where heart rate control cannot be achieved using combination therapy.
References:
  1. 2016 ESC Guidelines for the management of atrial fibrillation
  2. https://www.nice.org.uk/guidance/cg180/resources/atrial-fibrillation-management-pdf-35109805981381 
  3. Pharmacologic Management of Newly Detected Atrial Fibrillation by AAFP, 2017
  4. Lexicomp